Option chain shows key data for Optimi Health's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Optimi Health.

Optimi Health (OTC:OPTHF) Stock, Option Chain

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

2-2-2

Cannabis

News

Psychedelics

Press Releases

OPTHF

Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships.

Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition

Canada

Markets

LULU

Canada Magic Mushrooms and MDMA market is hitting new milestones as canada has licensed Optimi to export psilocybin and MDMA to Australia

New Milestone In Psychedelics Market: Canadian Start-Up Will Export Psilocybin And MDMA To Australia

Psyched New - option 1

Biotech

AWKNF

BETRF

CMND

FLHLF

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

MDXXF

MNMD

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans&#39; Trips And More

OPTIMI HEALTH CORP by OPTIMI HEALTH CORP.

Optimi Health Corp

The CNN Money Fear and Greed index showed further improvement in overall market sentiment, but the index remained in the &#8220;Fear&#8221; zone on Tuesday.
U.S. stocks settled higher on Tuesday, with the Dow Jones index gaining more than 500 points during the session as investors bet on more domestic-friendly policies following Donald Trump&#8217;s inauguration on Jan. 20 as the 47th U.S. President.
All three major indices also recorded their first weekly gain of 2025. The Dow jumped 3.7%, while the S&amp;P 500 added 2.9% last week. The Nasdaq, meanwhile, surged 2.5% during the week to notch its strongest weekly performance since December.
D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) reported better-than-expected first-quarter results. 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) reported upbeat fourth-quarter 2024 results and initiated 2025 guidance.
Most sectors on the S&amp;P 500 closed on a positive note, with industrials, real estate, and health care stocks recording gains on Tuesday. However, energy stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 538 points to 44,025.81 on Tuesday. The S&amp;P 500 rose 0.88% to 6,049.24, while the Nasdaq Composite climbed 0.64% at 19,756.78 during Tuesday's session.
Investors are awaiting earnings results from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 40.8, the index remained in the &#8220;Fear&#8221; zone on Tuesday, versus a prior reading of 37.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock"> Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Trading Ideas

Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone

Hal Sperlich, the automotive genius behind the <a href="https://www.benzinga.com/news/24/04/38285214/fords-mustang-gallops-into-60th-year-still-a-pony-with-plenty-of-kick">Ford Mustang</a>, passed away on Monday at 95. 
What Happened: Sperlich is best known as the chief architect behind the Ford Mustang and the Chrysler minivan. A Detroit and Saginaw native, Sperlich trained to be an engineer at the University of Michigan. He joined Ford in 1957 as a product planner and went on to develop the Mustang.
After leaving Ford, Sperlich joined Chrysler in 1977 and directed the company&#8217;s engineering personnel to develop a front-wheel-drive platform that became the &#8220;K-Car&#8221; which later gave rise to the company&#8217;s minivans. He was inducted into the Automotive Hall of Fame in 2009.
The news of his passing was first<a href="https://www.autonews.com/executives/an-obituary-hal-sperlich/"> reported</a> by Automotive News.
Ford CEO Responds: Ford CEO Jim Farley expressed his condolences on Tuesday in a post on social media platform X. 
&#8220;We lost a product visionary in Hal Sperlich. He was also a friend and mentor to me, and many others.&nbsp; Hal was a dare-to-be-different product planner who had vision, passion and knowledge of a customers' wants and needs,&#8221; Farley said. The CEO noted that Sperlich was behind the Ford Fiesta in addition to <a href="https://www.benzinga.com/25/01/42938610/ford-sold-more-electric-mustangs-than-gas-mustangs-in-2024">the Mustang.</a>
&#8220;He didn't play it safe, and he was always focused on the whitespace&nbsp;and improving the company's capability.&nbsp;There are a lot of people who make great cars but so few who invent segments like Hal did with the Ford Mustang and later the Fiesta,&#8221; Farley said. &#8220;Our hearts go out to his family and friends.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We lost a product visionary in Hal Sperlich. He was also a friend and mentor to me, and many others.  Hal was a dare-to-be-different product planner who had vision, passion and knowledge of a customers' wants and needs. He didn't play it safe, and he was always focused on the… <a href="https://t.co/Gmh4Q1RU3f">https://t.co/Gmh4Q1RU3f</a>
&mdash; Jim Farley (@jimfarley98) <a href="https://twitter.com/jimfarley98/status/1881820033632137417?ref_src=twsrc%5Etfw">January 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Photo courtesy: Ford

Tech

Ford Mustang Architect Hal Sperlich Dies At 95: 'Lot Of People Who Make Great Cars But So Few Who Invent Segments Like Hal Did,' Says Jim Farley

For the quarter ending 31 December 2024, BW Product Services reported an estimated gross profit of approximately USD 14 million. This gross profit primarily stems from a USD 58 million gain from realised trading positions, which was partially offset by an unrealised negative movement of USD 44 million due to the change in mark-to-market value of our open cargo contracts and hedging transactions.
After general and administrative expenses and income taxes, BW Product Services reported an estimated net profit of approximately USD 3 million for the quarter. The reported net profit includes accruals for personnel costs which may change subject to board approvals.

BWLP

BW LPG's Product Services Segment Delivers $58M In Realised Gains, Achieving $3M Net Profit In Q4 2024

A trader&#8217;s actions planted doubts on Tuesday after they bought over $5 million worth of Official Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) memecoin at the bottom just minutes after President Donald Trump said he knows little about it.
What Happened: In an X post, capital markets commentator The Kobeissi Letter drew attention to suspicious dealings shortly after Trump made his first public statement on his official coin.
The post noted that TRUMP fell over 33% three minutes after Trump&#8217;s remarks. At the exact bottom, a wallet scooped $5.09 million of the coin, which The Kobeissi Letter deemed as &#8220;one of the biggest single purchases&#8221; since the coin&#8217;s launch.
The subsequent purchase led to a quick recovery in the coin&#8217;s value, netting the trader $2.4 million in profits in just 14 minutes later. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is unusual: At 6:00 PM ET, President Trump says &quot;I don&#39;t know very much about it&quot; regarding his memecoin, <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a>. 3 minutes later, at 6:03 PM ET, <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a> fell over -33% and a wallet purchased $5.09 MILLION worth of it at the EXACT bottom. This is one of the biggest single… <a href="https://t.co/N1d7opCuga">https://t.co/N1d7opCuga</a> <a href="https://t.co/t5SSu7a1bI">pic.twitter.com/t5SSu7a1bI</a>
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1881844856039125287?ref_src=twsrc%5Etfw">January 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Kobeissi Letter called this development unusual. &#8220;Did someone know?&#8221; it said, alluding to insider training.
The findings were <a href="https://dexscreener.com/solana/a8nphpcjqtqhdquk35uj9hy2ysgxfkczgunwvkd3k7vc">drawn </a>from analytics platform DEX Screener and independently verified by Benzinga. The team behind Trump&#8217;s memecoin didn&#8217;t immediately return a request for comment.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/01/43087038/trump-names-uyeda-acting-sec-chair-as-crypto-regulations-get-set-for-a-makeover">Trump Names Uyeda Acting SEC Chair, Regulators Get Ready For Crypto Makeover</a>
Why It Matters: Trump <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43118779/trump-memecoin-regains-momentum-rallies-22-as-the-president-calls-billions-earned-through-the-venture-as-peanuts">appeared nonchalant </a>when he was asked about the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based memecoin&nbsp;during his first White House news conference.
"I&nbsp;don't&nbsp;know much about it other&nbsp;than I launched it. I&nbsp;heard it was very successful. I haven't&nbsp;checked where is it&nbsp;today,&#8221; he said.
However, when a journalist suggested that Trump had made "several billion dollars" from the venture, the president called it &#8220;peanuts.&#8221;
According to the coin's official website, entities linked to Trump&#8217;s family-owned conglomerate, The&nbsp;Trump Organization, <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43080060/donald-trump-and-melania-memecoins-combined-market-value-is-now-higher-than-that-of-warren-buffetts-hot-pick">control </a>80% of the coin&#8217;s supply. 
Price Action: At the time of writing, TRUMP was exchanging hands at $43.13, surging 20.53% in the last 24 hours, according to&nbsp;DEX Screener.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43086309/trumps-doge-committee-faces-lawsuit-over-alleged-federal-advisory-violations-and-lack-of-transparency">Trump&#8217;s DOGE Committee Faces Lawsuits Over Alleged Federal Advisory Violations, Lack Of Transparency</a></li>
</ul>
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

$TRUMP

Whale Investor Snaps Up $5 Million In Official Trump Coin Minutes After President Says, 'I Don't Know Much About It,' Marking One Of The Largest Purchases Since Launch

<ul>
<li>First set of abstracts released include Signatera&#x2122; data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date, along with the first read-outs in early cancer detection and tissue-free MRD</li>
<li>Additional Signatera data will be shared at ASCO GI on Jan. 25, 2025, including a late-breaking oral presentation on the CALGB (Alliance) / SWOG 80702 study</li>
</ul>

NTRA

Reported Earlier, Natera To Reveal New Insights On Signatera's Clinical Utility And Innovations In Tissue-Free MRD At ASCO GI 2025

Great Southern Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSBC#NASDAQ">GSBC</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.25 by 1.6 percent. This is a 14.41 percent increase over earnings of $1.11 per share from the same period last year. The company reported quarterly sales of $49.534 million which beat the analyst consensus estimate of $47.955 million by 3.29 percent. This is a 9.72 percent increase over sales of $45.147 million the same period last year.

Earnings

Earnings Beats

GSBC

Great Southern Bancorp Q4 2024 GAAP EPS $1.27 Beats $1.25 Estimate, Sales $49.534M Beat $47.955M Estimate

Since last quarter and through today, the Company has executed 650,000 square feet of leasing activity throughout its portfolio, underscoring the strength of Brandywine's core portfolio while demonstrating continued progress executing leases within its development pipeline. The fourth quarter leasing activity was the highest in 2024 and 18% higher than the fourth quarter of 2023. The weighted average lease term for the quarter was 9.4 years with total leasing activity for 2024 at 2.2 million square feet.

Reported Earlier, Brandywine Realty Trust Reports Strong Leasing Momentum With 650,000 Square Feet Leased In Q4 2024

SPHR

Reported Earlier, MSG Networks Seeks Neutral Arbitration To Restore Knicks, Rangers, Devils, And Islanders Coverage For Optimum Subscribers

HSDT

Reported Earlier, Helius Medical Technologies Executes Warrant Exercise Agreements For $3.7M Gross Proceeds, Introduces New Warrants

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 375,000 shares of common stock at the initial public offering price, representing 15% of the Shares sold in the Offering, less underwriting discounts and commissions, to cover over-allotments. The Offering is expected to close on or about January 23, 2025, subject to satisfaction of customary closing conditions.
The Company's common stock is expected to begin trading on the NYSE American on January 22, 2025, under the symbol "TOPP."&nbsp;

IPOs

TOPP

Reported Earlier, Toppoint Prices $10M Initial Public Offering Of 2.5M Common Shares At $4/Share

Production
<ul>
<li>Woodside's full-year 2025 production guidance is 186 – 196 MMboe (510 – 537 Mboe/day). This excludes volumes from Beaumont New Ammonia.</li>
<li>The approximate split by product type is:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">LNG</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~40%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pipeline gas</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~20%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Crude and condensate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~35%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Natural gas liquids</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~5%</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Woodside Provides 2025 Guidance: Sees 186–196 MMboe Production And $4.5B–5B Capex Allocation

Operations
<ul>
<li>Outstanding production from Sangomar with 75 Mboe/day produced in the quarter, driving record full-year production of 194 MMboe (530 Mboe/day), at the top end of the 2024 full-year production guidance range.</li>
<li>Quarterly production of 51.4 MMboe. (559 Mboe/day), down 3% from Q3 2024 due to lower seasonal demand at Bass Strait and an unplanned shutdown at Pluto, partly offset by increased production at Sangomar.</li>
<li>Quarterly revenue of $3,470 million, down 6% from Q3 2024 primarily due to lower seasonal demand at Bass Strait, partly offset by higher third-party LNG trades.</li>
<li>Sold 33.6% of produced LNG at prices linked to gas hub indices in the quarter (12.8% of total equity production), realising a 31% premium compared to oil-linked pricing.</li>
</ul>
Projects
<ul>
<li>The Scarborough Energy project was 78% complete at the end of the quarter, with the final Pluto Train 2 modules arriving at the Pluto LNG site in December. The project remains on target for first LNG cargo in 2026.</li>
<li>The Trion project was 20% complete at the end of the quarter, with construction of the floating production unit commencing in November. First oil is targeted for 2028.</li>
<li>Continued construction of the Beaumont New Ammonia project with Phase 1 of the project on track for start up in the second half of 2025.</li>
</ul>

Reported Earlier, Woodside Energy Q4 Revenue $3.47B Up From $3.355B YoY

Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea
Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:<a href="https://www.benzinga.com/stock/EVTd#TRQX">EVTd</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need.

Government

Evotec Partners with Yonsei University and Zymedi to Develop Lung Disease Therapies with $4.5M Grant

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) to report quarterly earnings at $1.34 per share on revenue of $11.01 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Abbott shares went up 0.08% to $116.88 in after-hours trading.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected fourth-quarter financial results. Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year. The company said it sees full-year revenue of $43.5 billion to $44.5 billion, up $0.5 billion from the company&#8217;s previous range. Netflix shares jumped 14.4% to $994.80 in the after-hours trading session.</li>
<li>Analysts are expecting Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to post quarterly earnings at $1.86 per share on revenue of $21.54 billion. The company will release earnings before the markets open. Procter &amp; Gamble shares gained 1% to $163.38 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) posted better-than-expected fourth-quarter financial results. The company reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $1.84 per share. The company reported quarterly sales of $1.39 billion which beat the analyst consensus estimate of $1.37 billion. Interactive Brokers shares gained 3.5% to $199.59 in the after-hours trading session.</li>
<li>Analysts expect Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) to post quarterly earnings at $2.01 per share on revenue of $22.44 billion before the opening bell. Johnson &amp; Johnson shares gained 0.6% to $149.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

IBKR

NFLX

Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday

The alliance combines the deep technical expertise of McKinsey's AI practice, QuantumBlack, and its track record of deploying and scaling AI solutions across industries with C3 AI's cutting-edge Enterprise AI software applications to help clients unlock the power of Enterprise AI and agentic AI to realize significant operational improvements and unlock new growth opportunities.

C3 AI And McKinsey Announce Alliance To Drive Rapid And Scalable AI Solutions For Global Enterprises

Announces intent to spin out and form a growth-oriented joint venture for LanzaX, the Company's&nbsp;differentiated synthetic biology platform, with Tharsis Capital joining as new LanzaX strategic partner to accelerate financing for the synbio development pipeline
Appoints new Interim Chief Financial Officer of LanzaTech to streamline biorefining platform growth priorities and heighten focus on cost reductions

LNZA

Reported Earlier, LanzaTech To Spin Out LanzaX Synbio Division In Joint Venture With Tharsis Capital; Appoints Justin Pugh As Interim CFO

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as major tech companies increasingly invest in AI-powered healthcare solutions.
What Happened: Isomorphic Labs, an Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary, is targeting major disease areas including oncology, cardiovascular conditions, and neurodegeneration, founder Demis Hassabis <a href="https://www.ft.com/content/41b51d07-0754-4ffd-a8f9-737e1b1f0c2e">told</a> Financial Times, speaking at the World Economic Forum in Davos. 
The company has already secured partnerships with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) for six drug development programs.
&#8220;It usually takes an average of five to 10 years to discover one drug. And maybe we could accelerate that 10 times, which would be an incredible revolution in human health,&#8221; said Hassabis, who recently received the Nobel Prize in Chemistry.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a>
Why It Matters: The announcement comes as Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) unveiled plans for an AI-driven cancer vaccine system capable of delivering personalized treatments within 48 hours. The initiative is <a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment">part of a $500 billion AI infrastructure project</a> called Stargate, developed in partnership with OpenAI and SoftBank Group.
Investment in AI-powered drug discovery has gained momentum, with ARK Invest CEO Cathie Wood projecting a $400 billion market opportunity in <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared">biologics over the next five years</a>. The sector has attracted significant attention from investors, though companies like Crispr Therapeutics AG and Intellia Therapeutics Inc. have shown considerable market volatility.
Isomorphic Labs, spun out from Google DeepMind in 2021, represents a growing trend of tech giants leveraging AI to streamline the traditionally lengthy and expensive drug development process. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119243/martin-shkreli-calls-ionq-and-rigetti-best-shorts-despite-recent-stock-gains-cites-offline-quantum-systems">Martin Shkreli Calls IonQ And Rigetti &#8216;Best Shorts&#8217; Despite Recent Stock Gains, Cites Offline Quantum Systems</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Health Care

CRSP

GOOGL

NTLA

ORCL

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

Elon Musk&#8217;s rocket manufacturing company <a href="https://www.benzinga.com/general/space/25/01/42755343/spacex-hits-new-milestone-in-2024-with-134-launches">SpaceX</a> on Tuesday launched its Falcon 9 rocket with 27 Starlink satellites to low-Earth orbit from California and subsequently landed a Falcon 9 rocket booster for the 400th time.
What Happened: Following separation from the rocket&#8217;s second stage, the booster that supported the Starlink mission landed back on Earth, enabling the company to reuse it for another mission.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Falcon lands for the 400th time! <a href="https://t.co/pwNCwAb3SK">pic.twitter.com/pwNCwAb3SK</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1881732223831080967?ref_src=twsrc%5Etfw">January 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The booster that supported the mission on Tuesday previously launched Oneweb 4, USSF-62, and other Starlink missions. The maximum number of missions to be flown by one Falcon 9 booster to date is 25.
Why It Matters: SpaceX is attempting to make its rockets reusable to bring down the cost of spaceflight as the cost of the first stage constitutes the majority of the cost of a new rocket. 
In July 2023, Musk warned that rocket manufacturers will&nbsp;<a href="https://www.benzinga.com/news/23/07/33383081/elon-musk-tells-rocket-makers-go-all-in-on-reusability-or-be-utterly-uncompetitive" target="_blank" rel="noreferrer noopener">need to go all-in on reusability</a>&nbsp;or risk being uncompetitive.
&#8220;Rockets are no different from other transport technologies, just harder to make reusable. No one would buy a single-use airplane, car, or even bicycle! You&#8217;d need to tow another car just for the return trip,&#8221; Musk said.
While the Falcon 9 is only partially reusable, SpaceX is attempting to make its Starship launch vehicle wholly reusable, landing back not just the booster but also the spacecraft. However, the Starship is currently only in the <a href="https://www.benzinga.com/25/01/43052113/bezos-musk-extend-cordial-support-despite-building-rivalry-between-their-rocket-companies">testing and development phase. </a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

SpaceX Falcon 9 Delivers 27 Starlink Satellites To Orbit, Marks 400th Booster Landing

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/JNJ/earnings">opening bell on Wednesday, Jan. 22, 2025.</a>
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.02 per share, down from $2.29 per share in the year-ago period. Johnson &amp; Johnson projects to report revenue of $22.45 billion for the recent quarter, compared to $21.39 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Johnson &amp; Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults with major depressive disorder who failed at least two oral antidepressants. Previously, it was only approved with oral antidepressants for treatment-resistant depression.
Johnson &amp; Johnson shares gained 0.8% to close at $148.15 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/jnj/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>B of A Securities analyst Tim Anderson maintained a Neutral rating and cut the price target from $166 to $160 on Jan. 17, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and cut the price target from $185 to $175 on Dec. 11, 2024. This analyst has an accuracy rate of 76%.</li>
<li>Guggenheim analyst Vamil Diwan maintained a Neutral rating and raised the price target from $156 to $162 on Nov. 6, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and raised the price target from $163 to $166 on Oct. 16, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $169 to $175 on Oct. 16, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-1024x572.png" alt="" class="wp-image-743946" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Price Target

Analyst Ratings

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

"Since our initial investment in 2021, we have observed the acceleration of Form Technologies' commercial success through its differentiated solutions-based offering and engineering excellence," said Aaron Rosen, Partner and Co-Head of Opportunistic Credit at Ares Management. "We believe that under David's leadership, Form Technologies is well-positioned to address the growing needs of its diversified customer base across key regions and sectors. We look forward to the exciting opportunities ahead as we support the team's goals for driving revenue growth and value creation."

ARES

Reported Earlier, Ares Management Becomes Majority Shareholder In Form Technologies With $304M Investment To Drive Long-Term Growth

Psychedelic stocks gain after FDA priority review for MDMA therapy

Oregon House passes bill to end hard drug decriminalization

Optimi Health CEO William Ciprick steps down, appoints Dane Stevens as interim CEO

ACRHF

ATAI

ATNF

CMPS

CRLBF

CURLF

CYBN

DRUG

ENVB

GHRS

GTBIF

IMBBY

JAPAY

MMNFF

MYCOF

NUMIF

RVVTF

SEEL

SPRC

General

Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research

Contracts

Optimi Health Provides Corporate Update

Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder

Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules

Small Cap

Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing

Optimi Health Awarded Drug Establishment Licence From Health Canada

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

CSE:OPTI

Optimi Health

Comments

Optimi Health

Optimi Health (OPTHF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga